液体活检
医学
危险分层
背景(考古学)
淋巴瘤
肿瘤科
疾病
活检
临床试验
模式
生物标志物
精密医学
内科学
重症监护医学
病理
癌症
生物
古生物学
社会科学
生物化学
社会学
作者
Steven Wang,Florent Moulière,D. Michiel Pegtel,Martine E.D. Chamuleau
标识
DOI:10.1016/j.molmed.2024.04.005
摘要
Diffuse large B cell lymphoma (DLBCL) exhibits significant biological and clinical heterogeneity that presents challenges for risk stratification and disease surveillance. Existing tools for risk stratification, including the international prognostic index (IPI), tissue molecular analyses, and imaging, have limited accuracy in predicting outcomes. The therapeutic landscape for aggressive lymphoma is rapidly evolving, and there is a pressing need to identify patients at risk of refractory or relapsed (R/R) disease in the context of personalized therapy. Liquid biopsy, a minimally invasive method for cancer signal detection, has been explored to address these challenges. We review advances in liquid biopsy strategies focusing on circulating nucleic acids in DLBCL patients and highlight their clinical potential. We also provide recommendations for biomarker-guided trials to support risk-adapted treatment modalities.
科研通智能强力驱动
Strongly Powered by AbleSci AI